Assembly Biosciences, Inc. (ASMB) total debt
Assembly Biosciences, Inc. (ASMB) carried total debt of $2.63M at the end of fiscal 2025 (December 31, 2025). That is 14.9% lower than the $3.09M of fiscal 2024. Figures as of 17 Nov 2026, 23:30 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total debt, fiscal 2025
- $2.63M
- Change on fiscal 2024
- −14.9%
- Highest on record
- $3.47Mfiscal 2022
- Lowest on record
- $2.34Mfiscal 2023
- Fiscal years on record
- 42022–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Assembly Biosciences, Inc. total debt, in more detail
Across the 4 fiscal years on record (2022–2025), the highest was $3.47M in fiscal 2022 and the lowest $2.34M in fiscal 2023.
Total debt was 0.0× shareholders' equity at the end of fiscal 2025.
Total debt by fiscal year
Assembly Biosciences, Inc. total debt, year by year
| Fiscal year | Total debt | Change | Year ended | Debt ÷ equity |
|---|---|---|---|---|
| 2025 | $2.63M | 14.9% down | 0.0× | |
| 2024 | $3.09M | 31.9% up | 0.1× | |
| 2023 | $2.34M | 32.4% down | 0.1× | |
| 2022 | $3.47M | — | 0.0× |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
How to read it
Debt magnifies results in both directions — set it against cash, equity and the profit available to pay the interest rather than reading it alone.
Assembly Biosciences, Inc., figure by figure
- Assembly Biosciences, Inc. market cap
- Assembly Biosciences, Inc. revenue
- Assembly Biosciences, Inc. earnings
- Assembly Biosciences, Inc. earnings per share (EPS)
- Assembly Biosciences, Inc. P/E ratio
- Assembly Biosciences, Inc. P/S ratio
- Assembly Biosciences, Inc. P/B ratio
- Assembly Biosciences, Inc. free cash flow
- Assembly Biosciences, Inc. operating margin
- Assembly Biosciences, Inc. dividend
- Assembly Biosciences, Inc. shares outstanding
- Assembly Biosciences, Inc. cash on hand
- Assembly Biosciences, Inc. total assets
- Assembly Biosciences, Inc. return on equity (ROE)
- Assembly Biosciences, Inc. return on invested capital (ROIC)
Assembly Biosciences, Inc. (ASMB) overview: price, valuation and scorecard
Assembly Biosciences, Inc. total debt: questions and answers
How much debt does Assembly Biosciences, Inc. have?
Assembly Biosciences, Inc. (ASMB) carried total debt of $2.63M at the end of fiscal 2025 (December 31, 2025). That is 14.9% lower than the $3.09M of fiscal 2024.
What are the highest and lowest total debt figures on record for Assembly Biosciences, Inc.?
Across the 4 fiscal years on record (2022–2025), the highest was $3.47M in fiscal 2022 and the lowest $2.34M in fiscal 2023.
How does Assembly Biosciences, Inc.'s debt compare with its equity?
Total debt was 0.0× shareholders' equity at the end of fiscal 2025.
How is Assembly Biosciences, Inc.'s total debt calculated?
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
Fiscal years are named for the calendar year they end in.
Learn: total debt
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Assembly Biosciences, Inc. (ASMB) total debt”, data as of 17 November 2026. https://funkfolio.com/stock/ASMB/total-debt
Underlying data: the company's filings with the SEC and Yahoo Finance.